



OPEN ACCESS

EDITED AND REVIEWED BY
Arun Srivastava,
University of Florida, United States

*CORRESPONDENCE
Li Ou
✉ ouxxx045@umn.edu

SPECIALTY SECTION
This article was submitted to
Vaccines and Molecular Therapeutics,
a section of the journal
Frontiers in Immunology

RECEIVED 21 November 2022
ACCEPTED 29 November 2022
PUBLISHED 18 January 2023

CITATION
Shen W, Liu S and Ou L (2023)
Corrigendum: rAAV immunogenicity,
toxicity, and durability in 255 clinical
trials: A meta-analysis.
Front. Immunol. 13:1104646.
doi: 10.3389/fimmu.2022.1104646

COPYRIGHT
© 2023 Shen, Liu and Ou. This is an
open-access article distributed under
the terms of the [Creative Commons
Attribution License \(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use,
distribution or reproduction in other
forums is permitted, provided the
original author(s) and the copyright
owner(s) are credited and that the
original publication in this journal is
cited, in accordance with accepted
academic practice. No use,
distribution or reproduction is
permitted which does not comply with
these terms.

Corrigendum: rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis

Weiran Shen¹, Shengjiang Liu² and Li Ou^{3,4*}

¹Obio Technologies, Shanghai, China, ²Avirmax Inc, Hayward, CA, United States, ³Genemagic Biosciences, Wallingford, PA, United States, ⁴Department of Pediatrics, University of Minnesota, Minneapolis, MN, United States

KEYWORDS

rAAV, clinical trials, immunogenicity, toxicity, neutralizing antibodies, immunosuppressants, capsids, gene therapy

A Corrigendum on

rAAV immunogenicity, toxicity, and durability in 255 clinical trials: A meta-analysis

by Shen W, Liu S and Ou L (2022) *Front. Immunol.* 13:1001263. doi: 10.3389/fimmu.2022.1001263

In the published article, there was an error in **Table 2** as published. Row 1, column 6 of the table should be “undisclosed” instead of “rBac-Sf9”. Furthermore, the row “Inflammatory arthritis” was removed as the death that occurred in that clinical trial was not AAV-related. The corrected **Table 2** and its caption “Table 2. Patient deaths that occurred in AAV-related clinical trials” appear below.

In the published article, there was an error in the legend for **Table 2** as published. We have removed one row in **Table 2**, so the Table legend needs to be updated accordingly. The corrected legend appears below.

“Two patient deaths were recently reported when Zolgensma is commercially used, and no detailed information was released yet (45). One patient death in a clinical trial for arthritis was excluded because it was deemed not be related with AAV (46). ALS, amyotrophic lateral sclerosis; GAN, giant axonal neuropathy; SMA, spinal muscular atrophy.”

In the published article, there was an error in **Figure 6** as published. In **Figure 6B**, both column “patient deaths” and “deaths per trial” for rBac-Sf9 should be 0. The corrected **Figure 6** and its caption “Figure 6. Manufacturing systems of 255 AAV clinical trials” appear below.


In the published article, there was an error. There was no patient death for the rBac/Sf9 system. Our information source on one trial was wrong.

A correction has been made to **Results, Production system**. This sentence previously stated: “Also, a total of 9 patient deaths occurred in 134 AAV trials using the HEK293 system, while there is one individual death for both rBac/Sf9 system (n=36) and producer cell line system (n=24) (**Figure 6B**).”

TABLE 2 Patient deaths that occurred in AAV-related clinical trials.

Disease	Trial ID	Drug name	Serotype	ROA	Production	Patient deaths	References
DMD	NCT03362502	PF-06939926	AAV9	Intravenous	Undisclosed	1	37
ALS	N/A	AAV-miR-SOD1	AAVrh10	Intrathecal	HEK293	1	38
MPS IIIA	NCT03612869	SAF-302	AAVrh10	Intracerebral	HEK293	1	39
GAN	NCT02362438	TSHA-120	AAV9	Intrathecal	HEK293	1	40
GM2 gangliosidosis	NCT04798235	TSHA-101	AAV9	Intrathecal	HEK293	1	41
SMA	NCT03461289	Zolgensma	AAV9	Intravenous	HEK293	1*	42
XLMTM	NCT03199469	AT132	AAV8	Intravenous	HEK293	4	43, 44

Two patient deaths were recently reported when Zolgensma is commercially used, and no detailed information was released yet (45). One patient death in a clinical trial for arthritis was excluded because it was deemed not be related with AAV (46). ALS, amyotrophic lateral sclerosis; GAN, giant axonal neuropathy; SMA, spinal muscular atrophy.



The corrected sentence appears below:

“Also, a total of 9 patient deaths occurred in 134 AAV trials using the HEK293 system, while there is one individual death for the producer cell line system (n=24) (Figure 6B).”

The authors apologize for these errors and state that they do not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.